Abstract
Objectives
The aim of the study was to determine if Lyprinol® is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).
Design
A double blind randomised placebo controlled trial.
Setting
Twenty well trained male volunteers, matched by VO2 max were randomly assigned to consume 200 mg of Lyprinol® or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.
Main outcome measures
Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run).
Results
No statistically significant differences were identified in any parameters between the active and placebo groups at any time point.
Conclusion
After 2 months ingestion of Lyprinol® at the currently recommended dosage (200 mg/day) and a demanding eccentric exercise intervention, Lyprinol® did not convincingly affect DOMS and indicators of muscle damage.
The aim of the study was to determine if Lyprinol® is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).
Design
A double blind randomised placebo controlled trial.
Setting
Twenty well trained male volunteers, matched by VO2 max were randomly assigned to consume 200 mg of Lyprinol® or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.
Main outcome measures
Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96 h after the downhill run).
Results
No statistically significant differences were identified in any parameters between the active and placebo groups at any time point.
Conclusion
After 2 months ingestion of Lyprinol® at the currently recommended dosage (200 mg/day) and a demanding eccentric exercise intervention, Lyprinol® did not convincingly affect DOMS and indicators of muscle damage.
| Original language | English |
|---|---|
| Pages (from-to) | 311-318 |
| Number of pages | 8 |
| Journal | Complementary Therapies in Medicine |
| Volume | 19 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2011 |